| Project/Area Number |
16K19138
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Virology
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
KANAI YUTA 大阪大学, 微生物病研究所, 助教 (80506501)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
Kobayashi Takeshi 大阪大学, 微生物病研究所, 准教授 (90324847)
Kawagishi Takahiro 大阪大学, 微生物病研究所, 特任研究員 (90800029)
|
|---|
| Research Collaborator |
Matsuura Yoshiharu 大阪大学, 微生物病研究所, 教授 (50157252)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | レオウイルス / 癌 / 遺伝子治療 / 腫瘍溶解性ウイルス / 癌治療 / 腫瘍溶解ウイルス / 治療 |
|---|
| Outline of Final Research Achievements |
Mammalian Reovirus (MRV) has important capacity that MRV show selective oncolytic activity in cancer cells. Currently, wild type T3D-C strain, which displays significant oncolytic activity, is developed as viral oncolytic agent. We generated recombinant RGD-MRV which has integrin-interactive RGD motif in MRV sigma1 protein to enable infection to MRV-resistant cancer cells via MRV receptor independent manner. This RGD-MRV exhibited enhanced infectivity and oncolysis of reovirus-resistant cancer cell. We generated various RGD-MRV variants which possessed multiple RGD motif, but not positive synergistic effect was observed. We examined the oncolytic activity of RGD-MRV to tumour in mice, but there were no significant differences in the oncolytic effect between RGD-MRV and wild-type MRV. That was, particular cancer cells resistant to infection of wild-type MRV transformed to be sensitive when the cells established tumour under mice skin.
|
